Author

N. I. Vokes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:variant calling· 1

Frequent Co-Authors

C. J. Wu· 2 shared E. M. Van Allen· 2 shared J. Park· 2 shared R. Haq· 2 shared A. Giobbie-Hurder· 1 shared A. Imamovic· 1 shared A. Nagano· 1 shared A. Roesch· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Wu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

G. Tarantino, C. A. Ricker, A. Wang, W. Ge, T. J. Aprati, A. Y. Huang, S. Madha, J. Chen, Y. Shi, M. Glettig, D. T. Frederick, S. Freeman, M. M. Holovatska, M. P. Manos, L. Zimmer, , D. Liu

This study identifies genomic heterogeneity and ploidy as markers of intrinsic resistance to PD-1 blockade in metastatic melanoma, with a decision tree model predicting resistance with high confidence.

Science Advances · Nov 29, 2024Peer-reviewedCancer Biology

Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma

Z. Bakouny, A. Sadagopan, P. Ravi, N. Y. Metaferia, J. Li, S. AbuHammad, S. Tang, T. Denize, E. R. Garner, X. Gao, D. A. Braun, L. Hirsch, J. A. Steinharter, G. Bouchard, E. Walton, , S. R. Viswanathan

This study characterizes translocation renal cell carcinoma (tRCC) through integrated clinical and molecular analysis of 152 patients, identifying key features like MiT/TFE fusions, NRF2-driven antioxidant response, and differential treatment outcomes.

bioRxiv · Apr 14, 2021Cancer Biology

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance

D. R. Caswell, M. K. Mayekar, P. Gui, E. K. Law, N. I. Vokes, C. M. Ruiz, M. Dietzen, M. Angelova, C. Bailey, O. Pich, B. Bakker, W. Wu, T. J. Humpton, D. L. Kerr, W. Hill, , Argyr

This study shows that targeted cancer therapy induces APOBEC-mediated mutagenesis, promoting drug resistance by increasing genetic diversity through mechanisms involving NF-κB activation and reduced DNA repair.

bioRxiv · Dec 18, 2020Cancer Biology